Expereince and Passion

Our efforts ensure the needs, values and preferences of the patient are represented

Meet Our Team

Jeff Broderick Chief Executive Officer

Jeff has over 20 years experience creating award-winning web and mobile businesses. Jeff is a passionate innovator who utilizes emerging technologies to start companies that creatively fill gaps in existing markets. He specializes in startup environments at the conception stage where ideas become products and teams are assembled to bring those products to market. Companies include Beneufit, JB3 Industrial, CrowdOptic, LoanHounds (acquired by QuinStreet), StockPoint (acquired by Pinnacor).

Ken Kubota Chief Product Officer

Executive improving healthcare through the development of new products and services by integrating technology, big data, and advanced data analytics. Developed and launched first electronic home-based motor test battery trial for Parkinson’s disease in partnership with Intel and scientists worldwide. Director of Data Science The Michael J. Fox Foundation for Parkinson’s Research. University of California, Berkeley. Stanford University Graduate School of Business. CEO of RosettaMD, Managing Director Kinetics.

Jerome Lisk, MD, FAAN Medical Director

Dr. Lisk is a published, board certified neurologist with a fellowship in movement disorders. He is an investigator in over twenty national clinical research trials in Parkinson’s disease. Memberships include The American Academy of Neurology Digital Strategy Subcommittee, Texas Health Services Authority Board of Directors, The Movement Disorder Society, California State Athletic Commission. Board of Directors of the American Heart Association African-American Task Force, Alzheimer’s Association Board Member and 2010 NAACP Man of Valor Award.

Kathleen Meyer, MPH, Ph.D., DABT Pharmaceutical Science Strategist

Board-certified toxicologist specializing in the nonclinical development of small and large molecule therapeutics. She has directed toxicology, pharmacokinetics, bioanalytical development and animal resources groups, lead project teams and subteams, and mentored many scientists. She has experience defending nonclinical development plans to US, EU and Japanese regulatory authorities. Sangamo BioSciences, BioMarin, XOMA, Elan Pharmaceuticals.